Literature DB >> 32238460

Complement Deficiencies Result in Surrogate Pathways of Complement Activation in Novel Polygenic Lupus-like Models of Kidney Injury.

Sladjana Skopelja-Gardner1, Lucrezia Colonna1, Payton Hermanson1, Xizhang Sun1, Lena Tanaka1, Joyce Tai1, Yenly Nguyen1, Jessica M Snyder2, Charles E Alpers3, Kelly L Hudkins3, David J Salant4, YuFeng Peng5, Keith B Elkon5,6.   

Abstract

Lupus nephritis (LN) is a major contributor to morbidity and mortality in lupus patients, but the mechanisms of kidney damage remain unclear. In this study, we introduce, to our knowledge, novel models of LN designed to resemble the polygenic nature of human lupus by embodying three key genetic alterations: the Sle1 interval leading to anti-chromatin autoantibodies; Mfge8-/- , leading to defective clearance of apoptotic cells; and either C1q-/- or C3-/- , leading to low complement levels. We report that proliferative glomerulonephritis arose only in the presence of all three abnormalities (i.e., in Sle1.Mfge8 -/- C1q -/- and Sle1.Mfge8 -/- C3 -/- triple-mutant [TM] strains [C1q -/-TM and C3-/- TM, respectively]), with structural kidney changes resembling those in LN patients. Unexpectedly, both TM strains had significant increases in autoantibody titers, Ag spread, and IgG deposition in the kidneys. Despite the early complement component deficiencies, we observed assembly of the pathogenic terminal complement membrane attack complex in both TM strains. In C1q-/- TM mice, colocalization of MASP-2 and C3 in both the glomeruli and tubules indicated that the lectin pathway likely contributed to complement activation and tissue injury in this strain. Interestingly, enhanced thrombin activation in C3-/- TM mice and reduction of kidney injury following attenuation of thrombin generation by argatroban in a serum-transfer nephrotoxic model identified thrombin as a surrogate pathway for complement activation in C3-deficient mice. These novel mouse models of human lupus inform the requirements for nephritis and provide targets for intervention.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32238460      PMCID: PMC7365257          DOI: 10.4049/jimmunol.1901473

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  125 in total

Review 1.  Clearance of apoptotic cells in human SLE.

Authors:  U S Gaipl; A Kuhn; A Sheriff; L E Munoz; S Franz; R E Voll; J R Kalden; M Herrmann
Journal:  Curr Dir Autoimmun       Date:  2006

2.  Antibacterial and protective properties of monoclonal antibodies reactive with Escherichia coli O111:B4 lipopolysaccharide: relation to antibody isotype and complement-fixing activity.

Authors:  K Oishi; N L Koles; G Guelde; M Pollack
Journal:  J Infect Dis       Date:  1992-01       Impact factor: 5.226

3.  Identification of a factor that links apoptotic cells to phagocytes.

Authors:  Rikinari Hanayama; Masato Tanaka; Keiko Miwa; Azusa Shinohara; Akihiro Iwamatsu; Shigekazu Nagata
Journal:  Nature       Date:  2002-05-09       Impact factor: 49.962

4.  Effective treatment of autoimmune disease and progressive renal disease by mixed bone-marrow transplantation that establishes a stable mixed chimerism in BXSB recipient mice.

Authors:  B Wang; Y Yamamoto; N S El-Badri; R A Good
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

5.  Complement receptor 3 influences toll-like receptor 7/8-dependent inflammation: implications for autoimmune diseases characterized by antibody reactivity to ribonucleoproteins.

Authors:  Joanne H Reed; Manish Jain; Kristen Lee; Ekambar R Kandimalla; Mohd Hafeez Faridi; Jill P Buyon; Vineet Gupta; Robert M Clancy
Journal:  J Biol Chem       Date:  2013-02-05       Impact factor: 5.157

6.  Targeting complement component 5a promotes vascular integrity and limits airway remodeling.

Authors:  Mohammad A Khan; Christian Maasch; Axel Vater; Sven Klussmann; John Morser; Lawrence L Leung; Carl Atkinson; Stephen Tomlinson; Peter S Heeger; Mark R Nicolls
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

Review 7.  Update on Lupus Nephritis.

Authors:  Salem Almaani; Alexa Meara; Brad H Rovin
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-07       Impact factor: 8.237

Review 8.  The role of complement in the development of systemic lupus erythematosus.

Authors:  Anthony P Manderson; Marina Botto; Mark J Walport
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

Review 9.  Biomarkers and updates on pediatrics lupus nephritis.

Authors:  Michael Bennett; Hermine I Brunner
Journal:  Rheum Dis Clin North Am       Date:  2013-07-16       Impact factor: 2.670

Review 10.  Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus.

Authors:  Honglin Zhu; Hui Luo; Mei Yan; Xiaoxia Zuo; Quan-Zhen Li
Journal:  Genomics Proteomics Bioinformatics       Date:  2015-09-28       Impact factor: 7.691

View more
  2 in total

1.  C1q as a target molecule to treat human disease: What do mouse studies teach us?

Authors:  Kristina Schulz; Marten Trendelenburg
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786

2.  Acute skin exposure to ultraviolet light triggers neutrophil-mediated kidney inflammation.

Authors:  Sladjana Skopelja-Gardner; Joyce Tai; Xizhang Sun; Lena Tanaka; James A Kuchenbecker; Jessica M Snyder; Paul Kubes; Tomas Mustelin; Keith B Elkon
Journal:  Proc Natl Acad Sci U S A       Date:  2021-01-19       Impact factor: 12.779

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.